Press Releases

Novan Therapeutics' Abstract Accepted for Poster Session at 2014 Society for Investigative Dermatology Annual Meeting

April 23, 2014

Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced that data from the Phase 2 clinical trial in acne vulgaris with  its lead product candidate, SB204, has been accepted for presentation at the 2014 Annual Meeting of the Society for Investigative Dermatology (SID)  May 7-10, 2014 at the Albuquerque Convention Center in Albuquerque, New Mexico.  

Full Story

Novan Announces Positive Phase 2 Results for Novel Acne Treatment

March 21, 2014

Durham, NC – Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris. 

Full Story

 

Novan Selected to Present at Inaugural Dermatology Summit

December 12, 2013

Durham, NC – Novan Therapeutics announced today that the Company has been selected to present at the inaugural Dermatology Summit in San Francisco on January 12, 2014. 

Full Story

Novan Awarded $7.8 Million Contract by BARDA to Develop a Medical Countermeasure for Thermal Burns

August 26, 2013

DURHAM, N.C. – Novan Therapeutics announced today that the U.S. Department of Health and Human Services has entered into a contract with Novan to advance the development of a nitric oxide-based therapy as a topical treatment for thermal burns. 

Full Story

Close
Close